{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:56:37Z","timestamp":1793138197640,"version":"4.5.0"},"reference-count":36,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Craniopharyngiomas present unique challenges in surgical management due to their proximity to critical neurovascular structures. This systematic review investigates genetic and immunological markers as potential targets for therapy in craniopharyngiomas, assessing their involvement in tumorigenesis, and their influence on prognosis and treatment strategies. The systematic review adhered to PRISMA guidelines, with a thorough literature search conducted on PubMed, Ovid MED-LINE, and Ovid EMBASE. Employing MeSH terms and Boolean operators, the search focused on craniopharyngiomas, targeted or molecular therapy, and clinical outcomes or adverse events. Inclusion criteria encompassed English language studies, clinical trials (randomized or non-randomized), and investigations into adamantinomatous or papillary craniopharyngiomas. Targeted therapies, either standalone or combined with chemotherapy and\/or radiotherapy, were examined if they included clinical outcomes or adverse event analysis. Primary outcomes assessed disease response through follow-up MRI scans, categorizing responses as follows: complete response (CR), near-complete response (NCR), partial response, and stable or progressive disease based on lesion regression percentages. Secondary outcomes included treatment type and duration, as well as adverse events. A total of 891 papers were initially identified, of which 26 studies spanning from 2000 to 2023 were finally included in the review. Two tables highlighted adamantinomatous and papillary craniopharyngiomas, encompassing 7 and 19 studies, respectively. For adamantinomatous craniopharyngiomas, Interferon-2\u03b1 was the predominant targeted therapy (29%), whereas dabrafenib took precedence (70%) for papillary craniopharyngiomas. Treatment durations varied, ranging from 1.7 to 28 months. Positive responses, including CR or NCR, were observed in both types of craniopharyngiomas (29% CR for adamantinomatous; 32% CR for papillary). Adverse events, such as constitutional symptoms and skin changes, were reported, emphasizing the need for vigilant monitoring and personalized management to enhance treatment tolerability. Overall, the data highlighted a diverse landscape of targeted therapies with encouraging responses and manageable adverse events, underscoring the importance of ongoing research and individualized patient care in the exploration of treatment options for craniopharyngiomas. In the realm of targeted therapies for craniopharyngiomas, tocilizumab and dabrafenib emerged as prominent choices for adamantinomatous and papillary cases, respectively. While adverse events were common, their manageable nature underscored the importance of vigilant monitoring and personalized management. Acknowledging limitations, future research should prioritize larger, well-designed clinical trials and standardized treatment protocols to enhance our understanding of the impact of targeted therapies on craniopharyngioma patients.<\/jats:p>","DOI":"10.3390\/ijms25020723","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T10:06:43Z","timestamp":1704449203000},"page":"723","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-5000","authenticated-orcid":false,"given":"Edoardo","family":"Agosti","sequence":"first","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-5545","authenticated-orcid":false,"given":"Marco","family":"Zeppieri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Antonietti","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, \u201cSapienza\u201d University, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-0639","authenticated-orcid":false,"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Head-Neck and NeuroScience Department, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-1909","authenticated-orcid":false,"given":"Marco Maria","family":"Fontanella","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fiorindi","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Panciani","sequence":"additional","affiliation":[{"name":"Division of Neurosurgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Reyes, M., Taghvaei, M., Yu, S., Sathe, A., Collopy, S., Prashant, G.N., Evans, J.J., and Karsy, M. (2022). Targeted Therapy in the Management of Modern Craniopharyngiomas. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2704136"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"882381","DOI":"10.3389\/fendo.2022.882381","article-title":"Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm","volume":"13","author":"Calvanese","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clineuro.2018.01.039","article-title":"Craniopharyngiomas: A systematic review and evaluation of the current intratumoral treatment landscape","volume":"166","author":"Mrowczynski","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00381-020-04677-5","article-title":"Adamantinomatous craniopharyngioma in the molecular age and the potential of targeted therapies: A review","volume":"36","author":"Whelan","year":"2020","journal-title":"Childs Nerv. Syst."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/2019.10.FOCUS19705","article-title":"Adamantinomatous craniopharyngioma: Moving toward targeted therapies","volume":"48","author":"Hengartner","year":"2020","journal-title":"Neurosurg. Focus."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jannelli, G., Calvanese, F., Paun, L., Raverot, G., and Jouanneau, E. (2023). Current Advances in Papillary Craniopharyngioma: State-of-the-Art Therapies and Overview of the Literature. Brain Sci., 13.","DOI":"10.3390\/brainsci13030515"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_8","unstructured":"(2023, July 19). The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis|Request PDF. Available online: https:\/\/www.researchgate.net\/publication\/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3171\/jns.2000.92.2.0255","article-title":"Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas","volume":"92","author":"Jakacki","year":"2000","journal-title":"J. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3171\/2012.9.PEDS12225","article-title":"Pegylated interferon-\u03b1-2b for children with recurrent craniopharyngioma","volume":"10","author":"Yeung","year":"2012","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/neuonc\/noaa119","article-title":"Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: A Pediatric Brain Tumor Consortium report","volume":"22","author":"Goldman","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e28753","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT-activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1225734","DOI":"10.3389\/fendo.2023.1225734","article-title":"Tocilizumab for the fifth progression of cystic childhood craniopharyngioma\u2014A case report","volume":"14","author":"Buis","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ando.2023.10.003","article-title":"First evidence of anti-VEGF efficacy in an adult case of adamantinomatous craniopharyngioma: Case report and illustrative review","volume":"84","author":"Calvanese","year":"2023","journal-title":"Ann. D\u2019endocrinologie"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"djv310","DOI":"10.1093\/jnci\/djv310","article-title":"Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy","volume":"108","author":"Brastianos","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11102-015-0663-4","article-title":"Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor","volume":"19","author":"Aylwin","year":"2016","journal-title":"Pituitary."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2217\/cns-2016-0034","article-title":"BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors","volume":"6","author":"Roque","year":"2017","journal-title":"CNS Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s00701-017-3311-0","article-title":"Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy","volume":"159","author":"Rostami","year":"2017","journal-title":"Acta Neurochir."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3171\/2017.11.JNS172373","article-title":"Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: Case report","volume":"130","author":"Himes","year":"2018","journal-title":"J. Neurosurg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.32197","article-title":"Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations","volume":"125","author":"Juratli","year":"2019","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.18632\/oncotarget.27203","article-title":"Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: A case report","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3171\/2019.8.JNS19643","article-title":"Dual BRAF\/MEK therapy in BRAF V600E-mutated primary brain tumors: A case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity","volume":"133","author":"Bernstein","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_24","first-page":"vdaa141","article-title":"Medical debulking with BRAF\/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma","volume":"2","author":"Guyon","year":"2020","journal-title":"Neurooncol Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2020.7624","article-title":"Successful Use of BRAF\/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma","volume":"18","author":"Khaddour","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1212\/WNL.94.15_supplement.867","article-title":"Initial Presentation of Papillary Craniopharyngioma with BRAF Mutation Treated with Adjuvant Chemotherapy (867)","volume":"94","author":"Gopal","year":"2020","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00280-021-04234-0","article-title":"BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: A case series","volume":"87","author":"Butt","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"bvab043","DOI":"10.1210\/jendso\/bvab043","article-title":"Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor","volume":"5","author":"Chik","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/jcpt.13600","article-title":"Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift","volume":"47","author":"Nussbaum","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11102-023-01339-y","article-title":"Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma","volume":"26","author":"Lin","year":"2023","journal-title":"Pituitary"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2213329","article-title":"BRAF\u2013MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas","volume":"389","author":"Brastianos","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"e40190","article-title":"Concurrent Radiation and Targeted Therapy for Papillary Craniopharyngioma: A Case Report","volume":"15","author":"Shah","year":"2023","journal-title":"Cureus"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.wneu.2023.08.137","article-title":"Case Report: Successful Use of BRAF\/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma","volume":"180","author":"Wu","year":"2023","journal-title":"World Neurosurg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00701-019-03939-9","article-title":"Endoscopic endo- and extra-orbital corridors for spheno-orbital region: Anatomic study with illustrative case","volume":"161","author":"Pineda","year":"2019","journal-title":"Acta Neurochir."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1636.17912","article-title":"Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part. I: Therapeutic strategies","volume":"100","author":"Ganau","year":"2014","journal-title":"Tumori"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5301\/tj.5000215","article-title":"Radiosurgical options in neuro-oncology: A review on current tenets and future opportunities. Part. II: Adjuvant radiobiological tools","volume":"101","author":"Ganau","year":"2015","journal-title":"Tumori"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/723\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:40:57Z","timestamp":1760103657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/2\/723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25020723"],"URL":"https:\/\/doi.org\/10.3390\/ijms25020723","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}